PubRank

Gérald Simonneau

Author PubWeight™ 181.29‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005 9.27
2 Treatment of pulmonary arterial hypertension. N Engl J Med 2004 6.88
3 Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006 6.06
4 Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010 5.87
5 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 2015 5.24
6 Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 2013 4.98
7 Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002 4.79
8 Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005 2.98
9 Pulmonary arterial hypertension in patients treated by dasatinib. Circulation 2012 2.87
10 Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. Circulation 2013 2.64
11 Chronic thromboembolic pulmonary hypertension. Circulation 2006 2.58
12 Dysregulated renin-angiotensin-aldosterone system contributes to pulmonary arterial hypertension. Am J Respir Crit Care Med 2012 2.52
13 Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2008 2.48
14 New formula for predicting mean pulmonary artery pressure using systolic pulmonary artery pressure. Chest 2004 2.47
15 Is pulmonary arterial hypertension really a late complication of systemic sclerosis? Chest 2009 2.40
16 Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. Eur Heart J 2006 2.34
17 Vascular and right ventricular remodelling in chronic thromboembolic pulmonary hypertension. Eur Respir J 2012 2.32
18 Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. N Engl J Med 2015 2.23
19 CX(3)C chemokine fractalkine in pulmonary arterial hypertension. Am J Respir Crit Care Med 2002 2.15
20 C-kit-positive cells accumulate in remodeled vessels of idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2011 2.12
21 Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era. Am J Respir Crit Care Med 2007 2.03
22 Chronic thromboembolic pulmonary hypertension (CTEPH): results from an international prospective registry. Circulation 2011 1.92
23 Severe pulmonary hypertension during pregnancy: mode of delivery and anesthetic management of 15 consecutive cases. Anesthesiology 2005 1.88
24 Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2005 1.82
25 Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease. Chest 2004 1.72
26 Portopulmonary hypertension: survival and prognostic factors. Am J Respir Crit Care Med 2008 1.71
27 Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study. Chest 2003 1.71
28 Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial. J Am Coll Cardiol 2008 1.69
29 Pulmonary Langerhans cell histiocytosis-associated pulmonary hypertension: clinical characteristics and impact of pulmonary arterial hypertension therapies. Chest 2012 1.68
30 Selexipag for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med 2015 1.62
31 2015 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension. Rev Esp Cardiol (Engl Ed) 2016 1.61
32 Intravenous epoprostenol in inoperable chronic thromboembolic pulmonary hypertension. J Heart Lung Transplant 2007 1.58
33 Potts shunt in children with idiopathic pulmonary arterial hypertension: long-term results. Ann Thorac Surg 2012 1.54
34 IgG from patients with pulmonary arterial hypertension and/or systemic sclerosis binds to vascular smooth muscle cells and induces cell contraction. Ann Rheum Dis 2011 1.53
35 Role of endothelium-derived CC chemokine ligand 2 in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2007 1.52
36 Stress Doppler echocardiography in relatives of patients with idiopathic and familial pulmonary arterial hypertension: results of a multicenter European analysis of pulmonary artery pressure response to exercise and hypoxia. Circulation 2009 1.50
37 Clinical outcomes of pulmonary arterial hypertension in patients carrying an ACVRL1 (ALK1) mutation. Am J Respir Crit Care Med 2010 1.50
38 Characterization of pulmonary arterial hypertension patients walking more than 450 m in 6 min at diagnosis. Chest 2010 1.48
39 Prognostic factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 2003 1.46
40 Pre-implantation genetic diagnosis in pulmonary arterial hypertension due to BMPR2 mutation. Eur Respir J 2012 1.45
41 Pulmonary veno-occlusive disease: clinical, functional, radiologic, and hemodynamic characteristics and outcome of 24 cases confirmed by histology. Medicine (Baltimore) 2008 1.43
42 Fibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases. Hum Pathol 2007 1.42
43 Pulmonary hypertension: CT of the chest in pulmonary venoocclusive disease. AJR Am J Roentgenol 2004 1.41
44 Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension: a retrospective analysis of twenty-three cases. Arthritis Rheum 2008 1.40
45 Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 2004 1.40
46 Left ventricular ejection time in acute heart failure complicating precapillary pulmonary hypertension. Chest 2013 1.39
47 Chemokine RANTES in severe pulmonary arterial hypertension. Am J Respir Crit Care Med 2002 1.38
48 Sildenafil for pulmonary arterial hypertension: still waiting for evidence. Am J Respir Crit Care Med 2004 1.38
49 Screening for pulmonary arterial hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long-term survival. Arthritis Rheum 2011 1.35
50 Diagnostic strategy for patients with suspected pulmonary embolism: a prospective multicentre outcome study. Lancet 2002 1.32
51 Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension. Chest 2006 1.29
52 HIV-associated pulmonary arterial hypertension: survival and prognostic factors in the modern therapeutic era. AIDS 2010 1.27
53 Absence of influence of gender and BMPR2 mutation type on clinical phenotypes of pulmonary arterial hypertension. Respir Res 2010 1.19
54 Pulmonary arterial hypertension. Orphanet J Rare Dis 2013 1.18
55 Evaluation of various empirical formulas for estimating mean pulmonary artery pressure by using systolic pulmonary artery pressure in adults. Chest 2008 1.16
56 Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension. Adv Ther 2009 1.10
57 Autocrine fibroblast growth factor-2 signaling contributes to altered endothelial phenotype in pulmonary hypertension. Am J Respir Cell Mol Biol 2010 1.08
58 Future perspectives for the treatment of pulmonary arterial hypertension. J Am Coll Cardiol 2009 1.08
59 Treatment of pulmonary arterial hypertension with targeted therapies. Nat Rev Cardiol 2011 1.08
60 Pulmonary veno-occlusive disease: recent progress and current challenges. Respir Med 2010 1.06
61 Current and future management of chronic thromboembolic pulmonary hypertension: from diagnosis to treatment responses. Proc Am Thorac Soc 2006 1.05
62 Out-of-proportion pulmonary hypertension and heart failure with preserved ejection fraction. Respiration 2012 1.03
63 Long-term response to calcium-channel blockers in non-idiopathic pulmonary arterial hypertension. Eur Heart J 2010 1.01
64 Severe pulmonary arterial hypertension in type 1 glycogen storage disease. Eur J Pediatr 2002 1.01
65 Pulmonary arterial hypertension: a rare complication of primary Sjögren syndrome: report of 9 new cases and review of the literature. Medicine (Baltimore) 2007 0.97
66 Pulmonary arterial hypertension in ANCA-associated vasculitis. Sarcoidosis Vasc Diffuse Lung Dis 2006 0.96
67 Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil. Rheumatology (Oxford) 2009 0.96
68 Increased oxidative stress and severe arterial remodeling induced by permanent high-flow challenge in experimental pulmonary hypertension. Respir Res 2011 0.95
69 Identification of target antigens of antifibroblast antibodies in pulmonary arterial hypertension. Am J Respir Crit Care Med 2008 0.94
70 Treatment of pulmonary arterial hypertension with bosentan: from pathophysiology to clinical evidence. Expert Opin Pharmacother 2005 0.93
71 Controversies, uncertainties and future research on the treatment of chronic thromboembolic pulmonary hypertension. Proc Am Thorac Soc 2006 0.93
72 Diagnostic value of D-dimer in patients with suspected pulmonary embolism: results from a multicentre outcome study. Thromb Res 2006 0.92
73 Pulmonary arterial hypertension associated with systemic sclerosis in patients with functional class II dyspnoea: mild symptoms but severe outcome. Rheumatology (Oxford) 2010 0.92
74 Systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease: impact of pulmonary arterial hypertension therapies. Arthritis Rheum 2011 0.91
75 Long-term outcome of double-lung and heart-lung transplantation for pulmonary hypertension: a comparative retrospective study of 219 patients. Eur J Cardiothorac Surg 2010 0.91
76 Targets of anti-endothelial cell antibodies in pulmonary hypertension and scleroderma. Eur Respir J 2011 0.90
77 Pulmonary hypertension in patients with neurofibromatosis type I. Medicine (Baltimore) 2011 0.90
78 Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: an observational study. J Heart Lung Transplant 2011 0.90
79 Dynamic respiratory mechanics and exertional dyspnoea in pulmonary arterial hypertension. Eur Respir J 2012 0.90
80 Idiopathic pulmonary arterial hypertension and pulmonary veno-occlusive disease: similarities and differences. Semin Respir Crit Care Med 2009 0.90
81 Clinical worsening in trials of pulmonary arterial hypertension: results and implications. Curr Opin Pulm Med 2010 0.89
82 An extreme consequence of splenectomy in dehydrated hereditary stomatocytosis: gradual thrombo-embolic pulmonary hypertension and lung-heart transplantation. Hemoglobin 2003 0.88
83 Therapeutic advances in pulmonary arterial hypertension. Ther Adv Respir Dis 2008 0.88
84 Human herpes virus 8 in HIV and non-HIV infected patients with pulmonary arterial hypertension in France. AIDS 2005 0.87
85 Pharmacokinetic evaluation of sildenafil as a pulmonary hypertension treatment. Expert Opin Drug Metab Toxicol 2013 0.85
86 Pulmonary arterial hypertension and its association with HIV infection: an overview. AIDS 2008 0.85
87 Pulmonary hypertension in lymphangioleiomyomatosis: characteristics in 20 patients. Eur Respir J 2012 0.85
88 Pulmonary hypertension associated with benfluorex exposure. Eur Respir J 2012 0.85
89 Characteristics of pulmonary arterial hypertension in affected carriers of a mutation located in the cytoplasmic tail of bone morphogenetic protein receptor type 2. Chest 2015 0.85
90 EBUS-TBNA in the differential diagnosis of pulmonary artery sarcoma and thromboembolism. Eur Respir J 2012 0.85
91 Therapies for pulmonary arterial hypertension: where are we today, where do we go tomorrow? Eur Respir Rev 2013 0.84
92 Pulmonary arterial hypertension in a patient with Cowden syndrome and anorexigen exposure. Chest 2011 0.84
93 Evidence for the use of combination targeted therapeutic approaches for the management of pulmonary arterial hypertension. Respir Med 2010 0.84
94 Efficacy, safety and pharmacokinetics of bosentan in portopulmonary hypertension. Eur Respir J 2012 0.83
95 Hyperplasia of pulmonary artery smooth muscle cells is causally related to overexpression of the serotonin transporter in primary pulmonary hypertension. Chest 2002 0.83
96 Primary pulmonary hypertension: Current therapy. Prog Cardiovasc Dis 2002 0.82
97 Endothelin receptor antagonists for the treatment of pulmonary arterial hypertension. Expert Opin Pharmacother 2011 0.82
98 Perspective on the optimal endpoints for pulmonary arterial hypertension trials. Curr Opin Pulm Med 2010 0.81
99 Pulmonary arterial hypertension: bridging the present to the future. Eur Respir Rev 2012 0.81
100 N-acetylcysteine improves established monocrotaline-induced pulmonary hypertension in rats. Respir Res 2014 0.81
101 Drug Insight: endothelin-receptor antagonists for pulmonary arterial hypertension in systemic rheumatic diseases. Nat Clin Pract Rheumatol 2005 0.80
102 [Pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis]. Presse Med 2009 0.80
103 The need to move from 6-minute walk distance to outcome trials in pulmonary arterial hypertension. Eur Respir Rev 2013 0.80
104 Definition and classification of pulmonary hypertension. Handb Exp Pharmacol 2013 0.78
105 Effect of age on the performance of a diagnostic strategy based on clinical probability, spiral computed tomography and venous compression ultrasonography: the ESSEP study. Thromb Haemost 2005 0.78
106 Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension. J Clin Invest 2016 0.78
107 Pulmonary arterial hypertension and HIV infection. Semin Respir Crit Care Med 2009 0.78
108 Mediastinal fibrosis mimicking proximal chronic thromboembolic disease. Circulation 2012 0.78
109 [Pulmonary arterial hypertension associated with common diseases: connective-tissue diseases, HIV infection and portal hypertension]. Rev Prat 2008 0.78
110 Factors associated with diagnosis and operability of chronic thromboembolic pulmonary hypertension. A case-control study. Thromb Haemost 2013 0.78
111 Pulse wave reflection in pulmonary hypertension. J Am Coll Cardiol 2002 0.78
112 Pulmonary Hypertension Complicating Fibrosing Mediastinitis. Medicine (Baltimore) 2015 0.78
113 [Pulmonary hypertension associated with systemic sclerosis]. Ann Med Interne (Paris) 2002 0.77
114 Macitentan and pulmonary arterial hypertension. N Engl J Med 2014 0.77
115 Pulmonary veno-occlusive disease: the bête noire of pulmonary hypertension in connective tissue diseases? Presse Med 2011 0.77
116 Clinical challenges in pulmonary hypertension: Roger S. Mitchell lecture. Chest 2005 0.77
117 Drug-induced pulmonary arterial hypertension: a recent outbreak. Eur Respir Rev 2013 0.77
118 [2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension]. Kardiol Pol 2015 0.77
119 Ventilation/perfusion lung scan in pulmonary veno-occlusive disease. Eur Respir J 2011 0.76
120 A proof of concept for the detection and classification of pulmonary arterial hypertension through breath analysis with a sensor array. Am J Respir Crit Care Med 2013 0.76
121 [Pulmonary arterial hypertension]. Rev Prat 2008 0.76
122 Pulmonary arterial hypertension in familial hemiplegic migraine with ATP1A2 channelopathy. Eur Respir J 2013 0.75
123 Estimating right ventricular stroke work and the pulsatile work fraction in pulmonary hypertension. Chest 2013 0.75
124 Pulmonary venoocclusive disease and failure of specific therapy. Chest 2009 0.75
125 Vasodilators in patients with chronic obstructive pulmonary disease and pulmonary hypertension: not ready for prime time! Am J Respir Crit Care Med 2010 0.75
126 [Treatment of pulmonary arterial hypertension in 2011: what's new since the 2009 ERS/ESC guidelines?]. Presse Med 2011 0.75
127 [Introduction. Pulmonary arterial hypertension]. Presse Med 2010 0.75
128 A paradigm shift in pulmonary arterial hypertension management. Eur Respir Rev 2013 0.75
129 Editors' perspective and conclusions. AIDS 2008 0.75
130 [Eisenmenger syndrome. Role of rare diseases reference centers in the management of pulmonary hypertension in congenital heart diseases]. Presse Med 2009 0.75
131 [Perspectives on pulmonary vascular diseases]. Presse Med 2005 0.75
132 Developing a heart score: next steps. Am J Cardiol 2012 0.75
133 Clinical pharmacology of endothelin receptor antagonists used in the treatment of pulmonary arterial hypertension. Am J Cardiovasc Drugs 2015 0.75
134 [Deep venous thrombosis and pulmonary embolism]. Rev Prat 2002 0.75
135 Assessing effectiveness of pulmonary arterial hypertension therapies in daily practice. Curr Opin Pulm Med 2010 0.75
136 Renal replacement therapy in patients with severe precapillary pulmonary hypertension with acute right heart failure. Respiration 2012 0.75